What is the 13F Pro Quality Score for MGNX?

13F Pro ranks MACROGENICS INC (MGNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MGNX's current score at https://13fpro.ai/company/MGNX (free sign-up required for the full ranking).

Which hedge funds own the most MGNX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MGNX include ARMISTICE CAPITAL,, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MGNX as soon as new 13F filings post.

Where does 13F Pro source MGNX data?

All MACROGENICS INC fundamentals and ownership data come directly from SEC EDGAR. MACROGENICS INC files with the SEC under CIK 1125345. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MGNX in?

MACROGENICS INC (MGNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MGNX research updated on 13F Pro?

MGNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MACROGENICS INC(MGNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1125345 MGNX stock profile & AI dashboard →

13F Pro Quality Score

39.6/100

Rank #2,140 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

97.4/100

Profitability

29.1/100

Balance Sheet

22.9/100

Earnings Quality

1.3/100

Free Cash Flow

10.9/100

Institutional Flow

86.4/100

Revenue Scale

22.7/100

Dilution Risk

16.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MGNX Scores 40/100

exact factor attribution · 2026-09-11

MGNX's composite is driven by revenue growth and institutional flow, held back by free cash flow and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.5 pts

97th pct

Institutional flow

+1.8 pts

86th pct

Earnings growth

+0.7 pts

63th pct

Shareholder dilution

-1.7 pts

17th pct

Capital efficiency

-2.7 pts

23th pct

Profitability

-3.1 pts

29th pct

Scale

-4.1 pts

23th pct

Earnings quality

-4.9 pts

1th pct

Free cash flow

-5.9 pts

11th pct

Latest change (2026-08-16): 31 → 34 · ↑ Capital efficiency 6→25; ↑ Profit margin 9→19

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MGNX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for MACROGENICS INC (MGNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MGNX at 39.6/100 on a 32-signal composite quality model, placing it at rank #2,140 of 2,962 stocks — the bottom half of the AI-ranked universe. MGNX scores in the top quartile across revenue growth (97.4), institutional flow (86.4). Areas of concern include earnings quality (1.3) and free cash flow (10.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MACROGENICS INC reports quarterly revenue of $32.8M, net income of $19.5M, an operating margin of -42.2%. Top institutional holders of MGNX by reported 13-F value include ARMISTICE CAPITAL, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MGNX trades on the Nasdaq exchange and files with the SEC under CIK 1125345. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MACROGENICS INC directly from SEC EDGAR. MACROGENICS INC's 13F Pro composite quality score has ranged between 12 and 48 since 2021, currently 39.6 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about MACROGENICS INC

Quirks, history, and lore behind MGNX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on immuno-oncology.
2
The Numbers
A small-cap biotech with revenue largely derived from collaboration agreements rather than approved product sales — the classic pre-commercial drug-developer math.
3
The History
Founded in the late 1990s, the company built its entire platform around a proprietary antibody engineering technology it calls Fc Optimization, designed to make cancer-fighting antibodies hit harder.
4
The Secret
Its secret weapon is the DART platform — Dual-Affinity Re-Targeting — molecules engineered to grab two targets at once and redirect immune cells to destroy tumors.
5
The Lore
The company has inked partnerships with Zymeworks, Incyte, and Janssen, betting that its bispecific antibody approach will crack cancers that single-target drugs keep missing.
6
The Giveaway
Ticker MGNX, a Rockville, MD biotech whose name literally fuses "macro" with "genetics" — and whose DART-based pipeline is aimed squarely at blood cancers and solid tumors.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$32.8M

Net Income

Q2 2026

$19.5M

Free Cash Flow

Q2 2026

$-41.6M

Operating Margin

Q2 2026

-42.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-0.3% YoY

$149.5MFY 2025

FY22 $151.9MFY23 $58.7MFY24 $150.0MFY25 $149.5M

Net Income

-11.4% YoY

$-74.6MFY 2025

FY22 $-119.8MFY23 $-9.1MFY24 $-67.0MFY25 $-74.6M

Operating Income

+34.1% YoY

$-72.8MFY 2025

FY22 $-121.4MFY23 $-168.2MFY24 $-110.6MFY25 $-72.8M

EPS (Diluted)

-10.3% YoY

$-1.18FY 2025

FY22 $-1.95FY23 $-0.15FY24 $-1.07FY25 $-1.18

Total Assets

-1.8% YoY

$256.8MFY 2025

FY22 $280.5MFY23 $298.4MFY24 $261.7MFY25 $256.8M

Op. Cash Flow

-18.5% YoY

$-81.0MFY 2025

FY22 $-87.0MFY23 $-78.2MFY24 $-68.4MFY25 $-81.0M

Free Cash Flow

-15.1% YoY

$-83.0MFY 2025

FY22 $-90.6MFY23 $-80.0MFY24 $-72.1MFY25 $-83.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$149.5M -0.3%	$150.0M +155.3%	$58.7M -61.3%	$151.9M +96.2%	$77.4M -26.2%	$104.9M
Net Income	$-74.6M -11.4%	$-67.0M -639.3%	$-9.1M +92.4%	$-119.8M +40.7%	$-202.1M -55.8%	$-129.7M
Operating Income	$-72.8M +34.1%	$-110.6M +34.3%	$-168.2M -38.6%	$-121.4M +40.1%	$-202.8M -54.7%	$-131.1M
EPS (Diluted)	$-1.18 -10.3%	$-1.07 -613.3%	$-0.15 +92.3%	$-1.95 +42.1%	$-3.37 -36.4%	$-2.47
Total Assets	$256.8M -1.8%	$261.7M -12.3%	$298.4M +6.4%	$280.5M -16.3%	$335.2M -11.5%	$378.7M
Operating Cash Flow	$-81.0M -18.5%	$-68.4M +12.6%	$-78.2M +10.1%	$-87.0M +39.5%	$-143.8M -28.5%	$-111.9M
Free Cash Flow	$-83.0M -15.1%	$-72.1M +9.9%	$-80.0M +11.7%	$-90.6M +39.6%	$-150.0M -27.4%	$-117.8M

Get alerted when MGNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MACROGENICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MGNX

ARMISTICE CAPITAL, LLC
$23.1M5,006,752 sh
BlackRock, Inc.
$21.6M4,679,229 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.3M2,656,010 sh
RENAISSANCE TECHNOLOGIES LLC
$12.2M2,632,750 sh
ACADIAN ASSET MANAGEMENT LLC
$11.7M2,542,643 sh
BANK OF AMERICA CORP /DE/
$11.5M2,488,252 sh
TWO SIGMA INVESTMENTS, LP
$11.4M2,465,699 sh
MILLENNIUM MANAGEMENT LLC
$11.0M2,374,296 sh
WASATCH ADVISORS LP
$9.3M2,018,881 sh
RA CAPITAL MANAGEMENT, L.P.
$8.6M1,864,176 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$23.1M	5,006,752
BlackRock, Inc.	$21.6M	4,679,229
VANGUARD CAPITAL MANAGEMENT LLC	$12.3M	2,656,010
RENAISSANCE TECHNOLOGIES LLC	$12.2M	2,632,750
ACADIAN ASSET MANAGEMENT LLC	$11.7M	2,542,643
BANK OF AMERICA CORP /DE/	$11.5M	2,488,252
TWO SIGMA INVESTMENTS, LP	$11.4M	2,465,699
MILLENNIUM MANAGEMENT LLC	$11.0M	2,374,296
WASATCH ADVISORS LP	$9.3M	2,018,881
RA CAPITAL MANAGEMENT, L.P.	$8.6M	1,864,176

Companies Similar to MGNX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CCCC

C4 Therapeutics, Inc.

AI score

Similar quality profile · 11 shared holders

WASATCH ADVISORS LP RA CAPITAL MANAGEMENT, L.P.ADAR1 Capital Management, LLC

OVID

Ovid Therapeutics Inc.

AI score

Shared smart-money ownership · 9 shared holders

RA CAPITAL MANAGEMENT, L.P.Affinity Asset Advisors, LLC Informed Momentum Co LLC

VRCA

Verrica Pharmaceuticals Inc.

AI score

Similar quality profile · 4 shared holders

Affinity Asset Advisors, LLC ARMISTICE CAPITAL, LLC Velan Capital Investment Management LP

Equillium, Inc.

AI score

Shared smart-money ownership · 6 shared holders

RA CAPITAL MANAGEMENT, L.P.Affinity Asset Advisors, LLC DIADEMA PARTNERS LP

PRLD

Prelude Therapeutics Inc

AI score

Similar quality profile · 3 shared holders

RA CAPITAL MANAGEMENT, L.P.ADAR1 Capital Management, LLC Spark Investment Management LLC

EOLS

Evolus, Inc.

AI score

Similar quality profile · 5 shared holders

ARMISTICE CAPITAL, LLC DIADEMA PARTNERS LP PINNACLE ASSOCIATES LTD

VYGR

Voyager Therapeutics, Inc.

AI score

Shared smart-money ownership · 8 shared holders

ARMISTICE CAPITAL, LLC DIADEMA PARTNERS LP Susquehanna Portfolio Strategies, LLC

PTHS

Pelthos Therapeutics Inc.

AI score

Similar quality profile · 3 shared holders

DIADEMA PARTNERS LP Ikarian Capital, LLC Persistent Asset Partners Ltd

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MGNX on your watchlist

Track score changes the day MACROGENICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MGNX a good stock to buy?

13F Pro's AI-powered analysis of MACROGENICS INC (MGNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MGNX are available on the MGNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MGNX is classified as a small company.

Which hedge funds own MGNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MGNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MACROGENICS INC's investment landscape.